Company intelligence / Profile preview

Qiansin

Ownership: Private
Development stage: Other

Overview

Qiansin is an early-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics. The company primarily targets unmet medical needs in oncology and metabolic disorders. While specific details regarding its lead programs remain proprietary, Qiansin utilizes advanced medicinal chemistry and screening platforms to identify high-affinity candidates. The firm is part of the emerging wave of innovative biotech startups in the Asia-Pacific region aiming to translate basic research into clinical-stage assets.

Therapeutic areas: Metabolic DisordersOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Qiansin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qiansin.

Explore the full profile